Survival (From Transformation) According to Prognostic Variables in 26 Patients With Transformed MF/SS (Univariate Analysis)
| Grouping . | No. . | Median Survival (mo) . | % of Patients Alive at 2 yr (95% CI) . | P Value . |
|---|---|---|---|---|
| Age | ||||
| <60 yr | 8 | 15.3 | 38 (0-78) | .96 |
| ≥60 yr | 18 | 18.5 | 41 (17-65) | |
| Stage | ||||
| I-II | 17 | 22.4 | 50 (26-74) | .34 |
| III-IV | 9 | 16 | 17 (0-47) | |
| I-IIA | 7 | Not reached3-150 | 86 (60-100) | |
| IIB | 10 | 10 | 30 (1-59) | .04 |
| III | 2 | Not evaluable | Not evaluable | |
| IV | 7 | 15 | 3-151 | |
| I-IIA v | 7 | Not reached | .0035 | |
| IIB-IV | 19 | 14.5 | 86 (60-100) | |
| 23 (3-43) | ||||
| T staging | ||||
| T1 | 0 | Not applicable | Not applicable | .0182 |
| T2 | 8 | Not reached | 85 (58-100) | |
| T3 | 13 | 11.5 | 23 (0-46) | |
| T4 | 5 | 17 | 25 (0-68) | |
| Site of initial transformation | ||||
| Skin | ||||
| Yes | 24 | 17 | 39 (18-60) | .18 |
| No | 2 | 4 | 100 (not applicable) | |
| Lymph nodes | ||||
| Yes | 3 | 22 | 50 (0-100) | .46 |
| No | 23 | 17 | 39 (18-60) | |
| Depth of invasion | ||||
| >2.15 mm | 12 | 12 | 30 (6-54) | .15 |
| ≤2.15 mm | 12 | 20 | 50 (22-78) | |
| Histologic distribution | ||||
| Diffuse | 15 | 12.5 | 31 (7-55) | .17 |
| Lichenoid | 5 | Not reached | 60 (16-100) | |
| Patchy | 4 | 20 | 50 (10-100) | |
| LDH (U/L) | ||||
| High3-152 | 5 | 11 | 0 (0-55) | .10 |
| Low | 10 | 32.7 | 55 (22-88) | |
| β2M (mg/L) | ||||
| High (>2) | 9 | 16 | 50 (16-84) | .093 |
| Low (≤2) | 5 | 6 | 253-153 (0-68) |
| Grouping . | No. . | Median Survival (mo) . | % of Patients Alive at 2 yr (95% CI) . | P Value . |
|---|---|---|---|---|
| Age | ||||
| <60 yr | 8 | 15.3 | 38 (0-78) | .96 |
| ≥60 yr | 18 | 18.5 | 41 (17-65) | |
| Stage | ||||
| I-II | 17 | 22.4 | 50 (26-74) | .34 |
| III-IV | 9 | 16 | 17 (0-47) | |
| I-IIA | 7 | Not reached3-150 | 86 (60-100) | |
| IIB | 10 | 10 | 30 (1-59) | .04 |
| III | 2 | Not evaluable | Not evaluable | |
| IV | 7 | 15 | 3-151 | |
| I-IIA v | 7 | Not reached | .0035 | |
| IIB-IV | 19 | 14.5 | 86 (60-100) | |
| 23 (3-43) | ||||
| T staging | ||||
| T1 | 0 | Not applicable | Not applicable | .0182 |
| T2 | 8 | Not reached | 85 (58-100) | |
| T3 | 13 | 11.5 | 23 (0-46) | |
| T4 | 5 | 17 | 25 (0-68) | |
| Site of initial transformation | ||||
| Skin | ||||
| Yes | 24 | 17 | 39 (18-60) | .18 |
| No | 2 | 4 | 100 (not applicable) | |
| Lymph nodes | ||||
| Yes | 3 | 22 | 50 (0-100) | .46 |
| No | 23 | 17 | 39 (18-60) | |
| Depth of invasion | ||||
| >2.15 mm | 12 | 12 | 30 (6-54) | .15 |
| ≤2.15 mm | 12 | 20 | 50 (22-78) | |
| Histologic distribution | ||||
| Diffuse | 15 | 12.5 | 31 (7-55) | .17 |
| Lichenoid | 5 | Not reached | 60 (16-100) | |
| Patchy | 4 | 20 | 50 (10-100) | |
| LDH (U/L) | ||||
| High3-152 | 5 | 11 | 0 (0-55) | .10 |
| Low | 10 | 32.7 | 55 (22-88) | |
| β2M (mg/L) | ||||
| High (>2) | 9 | 16 | 50 (16-84) | .093 |
| Low (≤2) | 5 | 6 | 253-153 (0-68) |
Prognostic variables were determined at the time of transformation. Survival was calculated by Kaplan-Meier; Pvalue by log-rank or Gehan-Wilcoxon test, as appropriate.
Abbreviations: β2M, β2 microglobulin; CR, complete response; MF/SS, mycosis fungoides/Sezary syndrome; LDH, lactic dehydrogenase; PR, partial response; T1, limited patch/plaque (<10% of total skin surface); T2, generalized patch/plaque (≥10% of total skin surface); T3, tumors; T4, generalized erythroderma.
Five patients alive at median follow-up of 29 months.
Two of the patients were still alive, but the follow-up was less than 2 years (22 months).
≥10% above the upper limit of the normal range.
25% alive at 20 months.